Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery
- First Online:
- Cite this article as:
- Seo, SY. Arch. Pharm. Res. (2012) 35: 197. doi:10.1007/s12272-012-0221-9
- 359 Downloads
Multi-targeted hybrids combine two drugs in a single molecule to have greater medicinal effects than its individual components. Recently, a number of anti-cancer drug candidates such as CUDC-101 (Curis) have been designed based on linking properly two selected pharmacophores endowed with activity against different therapeutic targets.